Use of histone deacetylase inhibitors for the care of philadelphia-negative myeloproliferative syndromes

Abstract

The use of substances capable of inhibiting one or more enzymes of the histone deacetylase family (histone deacetylase inhibitors) for the therapeutic treatment of Philadelphia-negative myeloproliferative syndromes (polycythemia vera, essential thrombocythemia or idiopathic myelofibrosis) is described. The dosage of the above-mentioned substances is significantly lower than that normally used for the care of other tumour syndromes and may be from 10 to 150 mg/day/patient.

1 - 12 . (canceled) 
     
     
         13 . Method of treating Philadelphia-negative myeloproliferative syndromes in a patient suffering from said syndromes, said method comprising administering to said patient diethyl-[6-(4-hydroxycarbamoyl-phenylcarbamoyloxymethyl)-naphthalen-2-yl-methyl]-ammonium chloride, or other pharmaceutically acceptable salts and/or solvates, in a daily dosage amount of from 10 to 150 mg per patient. 
     
     
         14 . Method according to  claim 13 , wherein said diethyl-[6-(4-hydroxycarbamoyl-phenylcarbamoyloxymethyl)-naphthalen-2-yl-methyl]-ammonium chloride is in monohydrate form. 
     
     
         15 . Method according to  claim 13 , wherein said diethyl-[6-(4-hydroxycarbamoyl-phenylcarbamoyloxymethyl)-naphthalen-2-yl-methyl]-ammonium chloride is in monohydrate crystal form. 
     
     
         16 . Method according to  claim 13 , wherein said daily dosage is from 30 to 120 mg per patient. 
     
     
         17 . Method according to  claim 13 , wherein said daily dosage is from 50 to 100 mg per patient. 
     
     
         18 . Method according to  claim 13 , wherein said Philadelphia-negative myeloproliferative syndrome is polycythemia vera. 
     
     
         19 . Method according to  claim 13 , wherein said Philadelphia-negative myeloproliferative syndrome is essential thrombocythemia. 
     
     
         20 . Method according to  claim 13 , wherein said Philadelphia-negative myeloproliferative syndrome is primary myeofibrosis. 
     
     
         21 . Method according to  claim 13 , wherein said Philadelphia-negative myeloproliferative syndrome is secondary myelofibrosis. 
     
     
         22 . Method according to  claim 13 , wherein said diethyl-[6-(4-hydroxycarbamoyl-phenylcarbamoyloxymethyl)-naphthalen-2-yl-methyl]-ammonium chloride, or other pharmaceutically acceptable salts and/or solvates, is not administered in combination with other active principles. 
     
     
         23 . Method according to  claim 13 , wherein said diethyl-[6-(4-hydroxycarbamoyl-phenylcarbamoyloxymethyl)-naphthalen-2-yl-methyl]-ammonium chloride, or other pharmaceutically acceptable salts and/or solvates, is administered in combination with at least one other cytostatic active principle.